Technical Analysis for SNY - Sanofi

Grade Last Price % Change Price Change
B 51.3 1.20% 0.61
SNY closed up 1.2 percent on Friday, April 16, 2021, on 47 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SNY trend table...

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Cup with Handle Other 1.20%
Cup with Handle Other 2.11%
Overbought Stochastic Strength 2.11%
Cup with Handle Other 2.27%
Multiple of Ten Bullish Other 2.27%
Older End-of-Day Signals for SNY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sanofi Description

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Its principal products include Lantus and Apidra analogs of human insulin; Insuman, a range of human insulin solutions and suspensions; Amaryl, an oral once-daily sulfonylurea; BGStar and iBGStar blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aubagio, an oral immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for various cancer types; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company's products also consist of thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines include Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela oral phosphate binders used in patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis of certain joints; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products to treat fever, pain, and digestive health areas; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has alliance arrangements with Bristol-Myers Squibb, Regeneron, and Warner Chilcott. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Cancer Life Sciences Pharmaceutical Industry Pain Pharmaceuticals Health Sciences Prostate Cancer Phosphate Hypertension Animal Health Influenza Urea Dialysis Kidney Disease Multiple Sclerosis Glucose Healthcare Products Insulin Suspension Healthcare Product Osteoarthritis Colorectal Cancer Chronic Kidney Disease Health Care Products Cac 40 Vein Hepatotoxins Fever Platelet Pneumonia Bristol Myers Squibb Thrombosis Gaucher Disease Meningitis Phosphorus Consumer Health Care Consumer Health Care Products Deep Vein Thrombosis Pompe Disease Regeneron Clopidogrel Enzyme Replacement Therapies Glucose Meter

Is SNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.0
52 Week Low 44.11
Average Volume 2,014,734
200-Day Moving Average 49.67
50-Day Moving Average 48.33
20-Day Moving Average 49.82
10-Day Moving Average 50.37
Average True Range 0.62
ADX 28.41
+DI 37.29
-DI 14.92
Chandelier Exit (Long, 3 ATRs ) 49.62
Chandelier Exit (Short, 3 ATRs ) 50.11
Upper Bollinger Band 51.21
Lower Bollinger Band 48.43
Percent B (%b) 1.03
BandWidth 5.58
MACD Line 0.69
MACD Signal Line 0.63
MACD Histogram 0.0596
Fundamentals Value
Market Cap 128.77 Billion
Num Shares 2.51 Billion
EPS 1.94
Price-to-Earnings (P/E) Ratio 26.44
Price-to-Sales 2.83
Price-to-Book 1.68
PEG Ratio 3.24
Dividend 1.70
Dividend Yield 3.31%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.32
Resistance 3 (R3) 52.27 51.87 52.15
Resistance 2 (R2) 51.87 51.61 51.90 52.09
Resistance 1 (R1) 51.59 51.45 51.73 51.64 52.04
Pivot Point 51.19 51.19 51.27 51.22 51.19
Support 1 (S1) 50.91 50.93 51.05 50.96 50.56
Support 2 (S2) 50.51 50.77 50.54 50.51
Support 3 (S3) 50.23 50.51 50.45
Support 4 (S4) 50.28